GW Pharma Sativex formulation wins EPO patent
Sativex is also protected by a number of other patents related to different aspects of the product. GW chairman Geoffrey Guy said the grant of this patent is
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
Maintenance therapy using azathioprine or mycophenolate mofetil, helps consolidate remission and prevent relapse after the initial control of lupus nephritis. The 36-month, randomized, double-blind, double-dummy, phase 3 study